AIM
CRL icon

Advantage Investment Management’s Charles River Laboratories CRL Stock Holding History

Advantage Investment Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-154
Closed -$17K – 935
2018
Q4 		$17K Buy
+154
New +$19.3K 0.01% 539

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Advantage Investment Management's CRL Position: Q1 2019 in Review

Advantage Investment Management sold out of Charles River Laboratories (CRL) in Q1 2019, closing a stake of 154 shares — an estimated $17K sold.

Advantage Investment Management first reported a position in CRL in Q4 2018 and held it in 1 quarter. The position peaked at $17K in Q4 2018. 409 funds tracked by Wall St. Rank hold CRL as of Q1 2019.

  • Advantage Investment Management reported no remaining Charles River Laboratories position as of Q1 2019 after selling out during the quarter.
  • Advantage Investment Management sold 154 Charles River Laboratories shares in Q1 2019, an estimated $17K.
  • Advantage Investment Management first reported a position in Charles River Laboratories in Q4 2018 and held it in 1 quarter.
  • Advantage Investment Management's Charles River Laboratories position peaked at $17K in Q4 2018.
  • 409 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2019.

Based on Advantage Investment Management's 13F filing for Q1 2019, filed 15 May 2019.